| Serial Number | 90690440 |
| Word Mark | EIKON |
| Filing Date | Tuesday, May 4, 2021 |
| Status | 733 - FOURTH EXTENSION - GRANTED |
| Status Date | Thursday, September 5, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 2, 2022 |
| Goods and Services | Pharmaceutical drug discovery and development services; Scientific and medical research, development and information services in the fields of pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicine discovery and development; Drug discovery and pharmaceutical development services for the pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine industries; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for drug discovery and development; Providing temporary use of on-line non-downloadable software for tracking and measuring movement of proteins in living cells for pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine discovery and development services; Drug, pharmaceutical, biopharmaceutical, therapeutic, vaccine, diagnostic, and medicine research and development and testing; Research and development of new products in the fields of drugs, pharmaceuticals, biopharmaceuticals, therapeutics, vaccines, diagnostics, and medicines; Biomedical research and development services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Medical and clinical research and pharmaceutical development services to discover and develop medicines and vaccines in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Research, development, analysis, testing and consulting services in the fields of biochemistry, biotechnology, medicines, diagnostics, vaccines and pharmaceuticals; Scientific, medical, biological, biotechnology, biomedical, pharmaceutical research, development, analysis and testing services in the fields of cancer, immunological disorders, neuro-related disorders, cardio-vascular disorders, metabolic disorders, gastroenterology, dermatology, endocrinology, infectious diseases and ophthalmologic disorders; Scientific laboratory services, namely, live cell imaging analysis; Custom design and development of cells, cell lines and assays; Biomedical research services using a platform of biological tools and techniques for use in scientific research, drug and vaccine discovery and development; Providing a website featuring information in the fields of drug discovery and development, biochemistry, biotechnology, medicines, diagnostics, and pharmaceuticals; Provision of scientific, medical, biotechnology, biomedical, vaccine and pharmaceutical information regarding drug discovery, pharmaceutical products, vaccines and clinical trials |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, August 6, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | EIKON THERAPEUTICS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Hayward, CA 94545 |
| Party Name | EIKON THERAPEUTICS, INC. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Hayward, CA 94545 |
| Event Date | Event Description |
| Friday, May 7, 2021 | NEW APPLICATION ENTERED |
| Friday, August 6, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, September 13, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Monday, September 13, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Monday, September 13, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, January 6, 2022 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 5, 2022 | ASSIGNED TO EXAMINER |
| Thursday, January 6, 2022 | NON-FINAL ACTION WRITTEN |
| Thursday, January 6, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, June 25, 2022 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Saturday, June 25, 2022 | EXAMINERS AMENDMENT -WRITTEN |
| Saturday, June 25, 2022 | EXAMINERS AMENDMENT E-MAILED |
| Saturday, June 25, 2022 | EXAMINER'S AMENDMENT ENTERED |
| Saturday, June 25, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, July 13, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 2, 2022 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 2, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 27, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Monday, March 20, 2023 | SOU EXTENSION 1 FILED |
| Monday, March 20, 2023 | SOU TEAS EXTENSION RECEIVED |
| Monday, March 20, 2023 | SOU EXTENSION 1 GRANTED |
| Wednesday, March 22, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, September 22, 2023 | SOU TEAS EXTENSION RECEIVED |
| Friday, September 22, 2023 | SOU EXTENSION 2 FILED |
| Friday, September 22, 2023 | SOU EXTENSION 2 GRANTED |
| Tuesday, September 26, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU EXTENSION 3 FILED |
| Tuesday, March 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU EXTENSION 3 GRANTED |
| Thursday, September 5, 2024 | SOU TEAS EXTENSION RECEIVED |
| Thursday, September 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, September 5, 2024 | SOU EXTENSION 4 FILED |
| Thursday, September 5, 2024 | SOU EXTENSION 4 GRANTED |